February 02, 2018
Weil is advising Sanofi in its proposed €3.9 billion acquisition of Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®. Under the terms of the agreement, Sanofi will offer to acquire all of the outstanding ordinary shares of Ablynx, including shares represented by American Depositary Shares (ADSs) and warrants and convertible bonds for €45 per share in cash. The transaction was unanimously approved by both the Sanofi and Ablynx Boards of Directors. The consummation of the public offers is subject to customary conditions.
The Weil team advising Sanofi is led by Corporate Chairman and Mergers & Acquisitions partner Michael Aiello and includes Mergers & Acquisitions partner Matthew Gilroy; Mergers & Acquisitions associates Aileen Kim, Rob Cohen, Geoffrey Weinberg and Mario Carroll (Not Yet Admitted in New York); Technology & IP Transactions partner Jeffrey Osterman; Banking & Finance partners Olivier Jauffret and Daniel Dokos; Public Company Advisory Group partner Adé Heyliger; Antitrust partner John Scribner; Antitrust counsel Michael Naughton; Technology & IP Transactions associates Caroline Geiger, Christine Paik and Rami Sherman (Not Yet Admitted in New York); Antitrust associate Natalie Hayes; and Banking & Finance associate Kalish Mullen.